Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: December 10, 2004
Last updated: November 16, 2011
Last verified: November 2011
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2005
  Primary Completion Date: November 2005 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):